Ageas
24.2.2025 17:40:00 CET | Globenewswire | Press release
Ageas reports on the progress of share buy-back programme
Ageas reports on the progress of share buy-back programme
Further to the initiation of the share buy-back programme announced on 28 August 2024, Ageas reports the purchase of 72,457 Ageas shares in the period from 17-02-2025 until 21-02-2025.
| Date | Number of Shares | Total amount (EUR) | Average price (EUR) | Lowest price (EUR) | Highest price (EUR) |
| 17-02-2025 | 8,958 | 451,133 | 50.36 | 50.10 | 50.60 |
| 18-02-2025 | 16,395 | 828,766 | 50.55 | 50.25 | 50.75 |
| 19-02-2025 | 5,644 | 293,584 | 52.02 | 51.40 | 52.60 |
| 20-02-2025 | 25,000 | 1,280,359 | 51.21 | 51.00 | 52.20 |
| 21-02-2025 | 16,460 | 841,135 | 51.10 | 50.95 | 51.30 |
| Total | 72,457 | 3,694,976 | 51.00 | 50.10 | 52.60 |
Since the start of the share buy-back programme on 16 September 2024, Ageas has bought back 2,117,171 shares for a total amount of EUR 102,042,592. This corresponds to 1.13% of the total shares outstanding.
The overview relating to the share buy-back programme is available on our website.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
CGTN19.9.2026 08:41:28 CEST | Press release
CGTN：CGTN Poll | Why is the SCO Solution for Global Governance Drawing Wide Attention?
Teva Pharmaceutical Industries Ltd18.9.2026 22:32:00 CEST | Press release
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
Teva Pharmaceutical Industries Ltd18.9.2026 22:31:00 CEST | Press release
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
Teva Pharmaceutical Industries Ltd18.9.2026 22:30:00 CEST | Press release
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
Leading Edge Materials Corp.18.9.2026 20:30:00 CEST | Press release
LEADING EDGE MATERIALS REPORTS QUARTERLY RESULTS TO JULY 31, 2026 AND ANNOUNCES CLOSING OF THE SECOND TRANCHE OF PRIVATE PLACEMENT
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom